![](/img/cover-not-exists.png)
172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment
Ando, T., Yuki, S., Nakatsumi, H., Muranaka, T., Hosokawa, A., Tsuji, Y., Nakamura, M., Muto, O., Sasaki, T., Iwanaga, I., Hatanaka, K., Sato, A., Eto, K., Furukawa, K., Tateyama, M., Takahashi, Y., SVolume:
27
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw581.004
Date:
December, 2016
File:
PDF, 69 KB
2016